Claim Details
View detailed information about this claim and its related sources.
Claim Information
Complete details about this extracted claim.
- Claim Text
-
The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs.
- Simplified Text
-
Wuxi AppTec was involved in a quarter of drugs used in the US.
- Confidence Score
- 0.700
- Claim Maker
- Jacob Dreyer
- Context Type
- Opinion Essay
- Context Details
-
{ "date": "2025-08-17", "company": "Wuxi AppTec", "location": "United States", "statistic": "25 percent of drugs" } - Subject Tags
- UUID
- 9fdaec23-8100-4d21-8e0c-cbd8131efffc
- Vector Index
- ✗ No vector
- Created
- September 11, 2025 at 9:28 PM (2 days ago)
- Last Updated
- September 11, 2025 at 9:28 PM (2 days ago)
Original Sources for this Claim (1)
All source submissions that originally contained this claim.
51
claims
🔥
2 days ago
https://www.nytimes.com/2025/08/17/opinion/china-biotech.html?campaign_id=9&emc=edit_nn_20250817&instance_id=160714&nl=the-morning®i_id=122976029&segment_id=204065&user_id=b25c5730c89e0c73f75709d8f1254337
China's biotech sector is rapidly expanding, offering cheaper and faster drug manufacturing. This challenges US dominance, sparking debate on competition and collaboration.
Similar Claims (0)
Other claims identified as semantically similar to this one.
No similar claims found
This claim appears to be unique in the system.